Diagnosis of immune pathophysiology in patients with bone marrow failure
Author:
- 7 January 2023
- journal article
- research article
- Published by Springer Nature in International Journal of Hematology
- Vol. 119 (3) , 231-239
Abstract
Differential diagnosis of pancytopenia with bone marrow (BM) hypoplasia represented by aplastic anemia (AA) is often challenging for physicians, because no laboratory tests have been established, until recently, to distinguish immune-mediated BM failure, which includes acquired AA (aAA) and a subset of low-risk myelodysplastic syndrome (MDS), from non-immune BM failure, which is primarily caused by genetic abnormalities in hematopoietic stem cells (HSCs). HSCs of healthy individuals often undergo somatic mutations, and some acquire phenotypic changes that allow them to escape immune attack against themselves. Once an immune attack against HSCs occurs, HSCs that undergo somatic mutations survive the immune attack and continue to produce their progenies with the same genetic or phenotypic changes. The presence of mature blood cells derived from mutated HSCs in the peripheral blood serves as evidence of the immune-mediated destruction of HSCs. Glycosylphosphatidylinositol-anchored protein-deficient (GPI[−]) blood cells and HLA class I allele-lacking (HLA[−]) leukocytes are two major aberrant cell types that represent the immune mechanism underlying BM failure. This review focuses on the importance of identifying immune mechanisms using laboratory markers, including GPI(−) cells and HLA(−) leukocytes, in the management of BM failure.Keywords
Funding Information
- MEXT KAKENHI (Grant-in-Aid for Scientific Research (22K08473)
This publication has 37 references indexed in Scilit:
- Border between aplastic anemia and myelodysplastic syndromeInternational Journal of Hematology, 2013
- Increased plasma thrombopoietin levels in patients with myelodysplastic syndrome: a reliable marker for a benign subset of bone marrow failureHaematologica, 2013
- Comment to "Favorable outcome of patients who have 13q deletion: a suggestion for revision of the WHO 'MDS-U' designation" Haematologica. 2012;97(12):1845-9.Haematologica, 2013
- Favorable outcome of patients who have 13q deletion: a suggestion for revision of the WHO 'MDS-U' designationHaematologica, 2012
- Frequent loss of HLA alleles associated with copy number-neutral 6pLOH in acquired aplastic anemiaBlood, 2011
- SNP array–based karyotyping: differences and similarities between aplastic anemia and hypocellular myelodysplastic syndromesBlood, 2011
- Origin and fate of blood cells deficient in glycosylphosphatidylinositol‐anchored protein among patients with bone marrow failureBritish Journal of Haematology, 2009
- Minor population of CD55-CD59- blood cells predicts response to immunosuppressive therapy and prognosis in patients with aplastic anemiaBlood, 2006
- Quantitative analysis of bone marrow CD34 cells in aplastic anemia and hypoplastic myelodysplastic syndromesLeukemia, 2006
- A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndromeBlood, 2003